Key performance indicators
Novartis access-to-healthcare projects 2012
| Research & Development | FTEs1 | Value (USD millions)2 |
| Novartis Institute for Tropical Diseases | 104 | 15.7 |
| Novartis Vaccines Institute for Global Health | 34 | 7.7 |
| Novartis Institutes for BioMedical Research neglected disease programs | 47 | 10.6 |
| Total | 185 | 34.0 |
Patient assistance | Patients reached (thousands) | Value (USD millions)3 |
| Novartis Patient Assistance Foundation, Inc. | 100.0 | 500.0 |
| Glivec patient assistance4 | 52.3 | 1 036.2 |
| Tasigna patient assistance4 | 3.1 | 92.3 |
| Exjade patient assistance | 6.4 | 26.0 |
| Alcon medical missions5 | 712.2 | 41.2 |
| Alcon US patient assistance | 19.4 | 17.9 |
| Malaria/Coartem6 | 99 799.9 | 281.7 |
| Leprosy (WHO) | 266.1 | 4.8 |
| Tuberculosis | 97.3 | 2.5 |
| Fascioliasis/Egaten7 | 178.5 | 0.1 |
| Emergency relief (medicine donations) | – | 0.2 |
| Total | 101 235.2 | 2 002.9 |
Health systems strengthening | FTEs | People reached (thousands)8 | Patients reached (thousands) | Value (USD millions) |
| Novartis Foundation for Sustainable Development | 7 | 4 649.3 | – | 10.6 |
| Novartis research capacity-building programs | 4 | 0.5 | – | 3.5 |
| Social Business:9Arogya Parivar, Familia Nawiri | 563 | 2 565.9 | 248.1 | – |
| Total | 574 | 7 215.7 | 248.1 | 14.1 |
Grand total | 759 | 7.2 million | 101 million | 2.0 billion |
- Full-time equivalent positions and contractors
- Operating costs
- Wholesale acquisition cost (WAC) plus logistic costs for some programs
- Retail value for surgical products
- Value and patients include donations under shared contribution and co-pay models
- During 2012, 99.7 million Coartem treatments reached patients based on a preliminary analysis of local distribution. Of these, 59.5 million treatments came from shipments completed in 2011, and 40.2 million from shipments in 2012. A total of 98.1 million treatments were shipped in 2012. Value was calculated using the number of treatments shipped in 2012 and the ex-factory price of Coartem to private-sector purchasers in malaria-endemic developing countries, excluding private-sector buyers using the Affordable Medicines Facility for malaria.
- Manufacturing cost
- Via training and service delivery
- People reached via training
